Drugs / LY3023703
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01965782 | Oct 2013 | — | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT01849055 | May → Dec 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01632579 | Jun → Sep 2012 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01872910 | Jun → Oct 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3023703 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01632579 ↗ |
| Action | Inhibit | “selectively inhibited the prostaglandin E(PGE) surge” NCT01872910 ↗ |
| Route | Oral | “Up to 6 single escalating doses of LY3023703 \[0.1 milligram (mg) up to 60 mg\] administered orally” NCT01632579 ↗ |